Harrow Management
Management criteria checks 0/4
Harrow's CEO is Mark Baum, appointed in Apr 2012, has a tenure of 12.08 years. total yearly compensation is $15.26M, comprised of 4.5% salary and 95.5% bonuses, including company stock and options. directly owns 6.04% of the company’s shares, worth $22.29M. The average tenure of the management team and the board of directors is 1.7 years and 2.2 years respectively.
Key information
Mark Baum
Chief executive officer
US$15.3m
Total compensation
| CEO salary percentage | 4.5% |
| CEO tenure | 12.1yrs |
| CEO ownership | 6.0% |
| Management average tenure | 1.7yrs |
| Board average tenure | 2.2yrs |
Recent management updates
Recent updates
Harrow: The Bull Thesis Is On Track, But Short-Term Challenges Loom
May 02Harrow's Drug Iheezo Is Off To A Great Start
Feb 19Harrow: Temporary Disruption In Stock Price Creates Excellent Opportunity
Jan 30Harrow sells non‑ophthalmic compounding business, terms undisclosed
Oct 05Harrow Health soars ~27% on FDA nod of anesthesia gel for the surface of the eye
Sep 27SRK Capital - Harrow Health: Market Missing The Forest For The Trees
Aug 19These 4 Measures Indicate That Harrow Health (NASDAQ:HROW) Is Using Debt Extensively
Aug 11
Buy Deep Moated, Fast Growing, Superbly Managed Harrow Health Ahead Of New Product Launch
May 23Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?
May 12Is Harrow Health (NASDAQ:HROW) A Risky Investment?
Dec 15Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?
Aug 24Harrow Health prices 8.625% senior notes due 2026
Jun 15Harrow Health: An 8.3% Baby Bond Yield With Low Balance Sheet Leverage
May 28Shareholders Shouldn’t Be Too Comfortable With Harrow Health's (NASDAQ:HROW) Strong Earnings
May 18Harrow Health, Inc. (NASDAQ:HROW) Just Reported And Analysts Have Been Lifting Their Price Targets
Mar 11Announcing: Harrow Health (NASDAQ:HROW) Stock Increased An Energizing 299% In The Last Three Years
Mar 08CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$15m | US$680k | -US$24m |
| Sep 30 2023 | n/a | n/a | -US$14m |
| Jun 30 2023 | n/a | n/a | -US$16m |
| Mar 31 2023 | n/a | n/a | -US$18m |
| Dec 31 2022 | US$1m | US$609k | -US$14m |
| Sep 30 2022 | n/a | n/a | -US$23m |
| Jun 30 2022 | n/a | n/a | -US$24m |
| Mar 31 2022 | n/a | n/a | -US$21m |
| Dec 31 2021 | US$7m | US$565k | -US$18m |
| Sep 30 2021 | n/a | n/a | -US$10m |
| Jun 30 2021 | n/a | n/a | US$7m |
| Mar 31 2021 | n/a | n/a | US$10m |
| Dec 31 2020 | US$2m | US$570k | -US$3m |
| Sep 30 2020 | n/a | n/a | -US$2m |
| Jun 30 2020 | n/a | n/a | -US$22m |
| Mar 31 2020 | n/a | n/a | -US$24m |
| Dec 31 2019 | US$1m | US$489k | US$168k |
| Sep 30 2019 | n/a | n/a | US$16m |
| Jun 30 2019 | n/a | n/a | US$25m |
| Mar 31 2019 | n/a | n/a | US$29m |
| Dec 31 2018 | US$1m | US$411k | US$15m |
| Sep 30 2018 | n/a | n/a | -US$6m |
| Jun 30 2018 | n/a | n/a | -US$9m |
| Mar 31 2018 | n/a | n/a | -US$10m |
| Dec 31 2017 | US$913k | US$417k | -US$12m |
Compensation vs Market: Mark's total compensation ($USD15.26M) is above average for companies of similar size in the US market ($USD2.41M).
Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.
CEO
Mark Baum (51 yo)
12.1yrs
Tenure
US$15,256,463
Compensation
Mr. Mark L. Baum, J.D., Co-founded Harrow Health, Inc. (formerly, Imprimis Pharmaceuticals, Inc.) and has been Chief Executive Officer since April 1, 2012 and serves as Chairman of the Board since August 1...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 12.1yrs | US$15.26m | 6.04% $ 22.3m | |
| CFO & Corporate Secretary | 9.3yrs | US$7.13m | 1.61% $ 5.9m | |
| Chief Commercial Officer | 1.7yrs | US$5.82m | 0.72% $ 2.7m | |
| Chief Scientific Officer | 1.3yrs | no data | no data | |
| Director of Communications & Investor Relations | no data | no data | no data | |
| Vice President of Legal & Compliance | less than a year | no data | no data | |
| Chief of Staff | 1.7yrs | no data | no data | |
| Head of Regulatory Affairs & Pharmacovigilance | 1.2yrs | no data | no data |
1.7yrs
Average Tenure
51yo
Average Age
Experienced Management: HROW's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of the Board | 12.4yrs | US$15.26m | 6.04% $ 22.3m | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 4.2yrs | US$227.50k | no data | |
| Lead Independent Director | 2.2yrs | US$202.50k | no data | |
| Independent Director | 2.2yrs | US$205.00k | 0.13% $ 469.3k |
2.2yrs
Average Tenure
54yo
Average Age
Experienced Board: HROW's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.